The Division of Pharmacologic Therapies (DPT), part of SAMHSA’s Center for Substance Abuse Treatment (CSAT) manages the day-to-day oversight activities necessary to implement federal regulations on the use of substance use disorder medications such as methadone and buprenorphine for the treatment of opioid use disorder (OUD).
DPT supports the certification and accreditation of more than 1,900 opioid treatment programs (OTPs) that collectively treat more than 600,000 patients each year.
Learn more about SAMHSA’s certification and accreditation of OTPs and oversight of OTP Accrediting Bodies.
Learn about the different medications and counseling used to treat substance use disorder (SUD) approved by the Food and Drug Administration (FDA) to treat SUD.
Find information on SUD training or SAMHSA training and resources.
SAMHSA has developed a Buprenorphine Quick Start Guide (PDF | 1.4 MB) and pocket guide (PDF | 200 KB) for all practitioners seeking to prescribe buprenorphine.
Learn more about the statutes, regulations, and guidelines that govern MAT.